Lanadelumab shown to effectively reduce hereditary angioedema attacks in real-world study

Lanadelumab is highly effective in reducing hereditary angioedema (HAE) attacks, with significant improvements in attack-free rates observed as early as the first month of treatment and sustained over time, according to a study.

The retrospective study analyzed data from 198 patients with HAE types I or II, aged 12 and older, treated with lanadelumab.

Before starting treatment, none of the patients were free from attacks. However, within 12 months of starting lanadelumab therapy, 54.4% of patients experienced no attacks, and this improvement was maintained over a median follow-up period of 28.8 months. Monthly attack-free rates rose from 17.7% in the month prior to treatment to over 95% at several time points between 26 and 43 months post-treatment.

Patients who required dose interval adjustments also showed notable benefits, with cumulative attack-free rates increasing from 0% pre-treatment to 50% after treatment.

Reference
Magerl M, Bouillet L, Martinez-Saguer I, et al. Real-world Effectiveness of Lanadelumab in Hereditary Angioedema: Multi-country INTEGRATED Observational Study. J Allergy Clin Immunol Pract. 2024;S2213-2198(24)01250-9. doi: 10.1016/j.jaip.2024.12.008. Epub ahead of print. PMID: 39701274.